-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Bristol-Myers Squibb, Lowers Price Target to $78

Benzinga·10/26/2026 11:57:05
Diffusion vocale
Piper Sandler analyst David Amsellem maintains Bristol-Myers Squibb (NYSE:BMY) with a Overweight and lowers the price target from $82 to $78.